Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that ...

The degree to which someone trusts the information depicted in a chart can depend on their assumptions about who made the ...

Visual content depicting climate activists emphasizes emotion and disruption, contrasting with the rational, data-driven ...

Companies use customer data in their decision-making, but they must know how to wield it properly. Here is the best way to ...

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstr ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Two doses of 52-week nerandomilast reduced FVC decline vs. placebo in the subgroup of U.S. adults with idiopathic pulmonary fibrosis in the FIBRONEER-IPF trial, according to a presentation at the ...